{"id":"administration-of-ceralasertib-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting ATR, ceralasertib disrupts the cellular response to DNA damage, potentially sensitizing cancer cells to genotoxic stress and enhancing the efficacy of DNA-damaging agents.","oneSentence":"Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:50:17.957Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT03330847","phase":"PHASE2","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-07","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":273},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT02264678","phase":"PHASE1, PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer","enrollment":357},{"nctId":"NCT03740893","phase":"PHASE2","title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-10-15","conditions":"Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD","enrollment":119},{"nctId":"NCT05061134","phase":"PHASE2","title":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-08-11","conditions":"Melanoma","enrollment":194},{"nctId":"NCT03682289","phase":"PHASE2","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2019-01-17","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm","enrollment":89},{"nctId":"NCT05469919","phase":"PHASE1","title":"An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-09","conditions":"Advanced Solid Malignancies","enrollment":12},{"nctId":"NCT02937818","phase":"PHASE2","title":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-28","conditions":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","enrollment":72},{"nctId":"NCT03022409","phase":"PHASE1","title":"A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-18","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT04239014","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-08-07","conditions":"Ovarian Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Administration of ceralasertib monotherapy","genericName":"Administration of ceralasertib monotherapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceralasertib is an ATP-competitive inhibitor of the serine/threonine kinase ATR, which is involved in DNA damage response pathways. Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}